MCM
PLX icon

MAI Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

MAI Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63 Buy
+29
New +$72 ﹤0.01% 4830

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

MAI Capital Management's PLX Position: Q1 2026 in Review

MAI Capital Management opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 29 shares worth $63. The stake represents ﹤0.01% of the portfolio and ranks #4830 among its holdings.

99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • MAI Capital Management held 29 shares of Protalix BioTherapeutics worth $63 as of Q1 2026.
  • Protalix BioTherapeutics was a new MAI Capital Management position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4830 holding.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.